AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01968486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
Study NCT04401735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: PDRN injection to epidural space
Study NCT04401735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT04401735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline
Study NCT01493323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of personality traits
Description: suicide behaviour , psychic pain, social exclusion, decision making...
Study NCT01493323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of suicidal act
Description: suicide behaviour , psychic pain, social exclusion, decision making...
Study NCT01493323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Description: suicide behaviour , psychic pain, social exclusion, decision making...
Study NCT01493323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyber ball game
Description: functional neuroimaging
Study NCT04025346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Micro Crystalline Cellulose
Description: 1 capsule to be taken before breakfast.
Study NCT01493323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task
Description: functional neuroimaging
Study NCT01493323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcomputer
Description: functional neuroimaging
Study NCT01493323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study NCT01207700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW based intervention post ACS
Description: CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
Study NCT03701776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
Study NCT03701776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Standard of care
Study NCT03274284 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: chemoradiation in case of T1G3 BC after BCG failure.
Study NCT01233804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opting Out
Description: Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
Study NCT01187017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg
Study NCT01187017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 125 mg/m squared
Study NCT01571102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
Study NCT01571102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
Study NCT00524485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Study NCT00524485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Study NCT04306471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
Study NCT04306471 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Description: The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
Study NCT02359318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
Study NCT02359318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
Study NCT02359318 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
Study NCT02359318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
Study NCT03481478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MRI
Description: For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
Study NCT04605601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality treatment
Description: Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
Study NCT04605601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional physiotherapy
Description: As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
Study NCT00683436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipiplon
Description: bilayer tablets 6 mg
Study NCT00683436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00683436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambien CR
Description: Ambien CR 12.5 mg
Study NCT00683436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipiplon
Description: bilayer tablets 9 mg
Study NCT01153386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: Treprostinil diethanolamine sustained release oral tablets.
Study NCT01994252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical therapy plus ICD
Study NCT01994252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical therapy plus CRT/ICD
Study NCT04410497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Porcine xenograft (wound dressings)
Description: commercial porcine xenograft, derived from acellular dermis from porcine.
Study NCT04410497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver foam (wound dressings)
Description: commercial silver containing foam dressing
Study NCT03382132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: momHealth
Description: Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
Study NCT03382132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
Study NCT01009060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: Histamine H3 Antagonist
Study NCT01009060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GSK239512
Study NCT01304264 — intervention group
Intervention type: DEVICE
Intervention: Color Doppler Imaging
Description: Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
Study NCT02212639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
Study NCT01293903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qiliqiangxin capsule
Description: Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Study NCT01293903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03691493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03691493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study NCT03539406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB-NK cells
Description: Intraperitoneal allogeneic UCB-NK cells infusion
Study NCT03539406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cyclofosfamide/fludarabine treatment
Study NCT01628146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRACOR LASIK treatment
Description: The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
Study NCT02005549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
Study NCT02005549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
Study NCT02005549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
Study NCT00388986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po bid
Study NCT00388986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 10-20mg po daily
Study NCT05680714 — intervention group
Intervention type: OTHER
Intervention: Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention
Study NCT03617562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior Capsular Reconstruction
Description: Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
Study NCT03617562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Repair
Description: Rotator cuff is repaired with residual defect remaining.
Study NCT04187898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.
Study NCT04187898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.
Study NCT04187898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.
Study NCT03646591 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
Study NCT04187898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycles 1-4, 30 mins after TC chemotherapy.
Study NCT04187898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.
Study NCT04187898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.
Study NCT00287898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Genetic Counseling
Description: Participants will receive all genetic counseling via telephone
Study NCT00287898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: subjects will receive standard in-person genetic counseling
Study NCT02251015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal plate
Description: In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
Study NCT02251015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
Study NCT02251015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
Study NCT02163902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Study NCT02163902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Study NCT02536612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Opportunity for entry in lottery (each time, at months 3 and 6).
Study NCT02536612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lottery
Description: Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
Study NCT05414461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: PD-1 inhibitor-based combinaiton treatment
Study NCT01811771 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol vaccine
Description: Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
Study NCT00983346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.
Study NCT01575821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eucalyptus honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
Study NCT01575821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Labiatae honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
Study NCT01575821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
Study NCT01575821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silan date extract
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
Study NCT01363375 — intervention group
Intervention type: PROCEDURE
Intervention: Foot orthosis, footwear
Description: flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
Study NCT01363375 — intervention group
Intervention type: PROCEDURE
Intervention: Foot orthosis, Footwear
Description: flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
Study NCT01363375 — intervention group
Intervention type: PROCEDURE
Intervention: Foot orthosis, footwear
Description: flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
Study NCT02050438 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Study NCT01286675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15